SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant volatility and a steep sell-off after disclosing that Marvell canceled its purchase orders due to a confidentiality breach caused by public remarks from management. The community is sharply divided, with many retail investors expressing frustration over the lack of transparency while others view the dip as an opportunity to accumulate shares, betting on the long-term viability of the company's photonics technology.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is surging toward record highs, driven by explosive AI-related demand for its NAND memory and intense speculation surrounding a potential stock split ahead of its upcoming earnings report. The community remains deeply divided, with bulls pointing to robust fundamentals and a 'memory supercycle,' while bears remain skeptical of the stock's parabolic valuation and fear an imminent correction.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant market activity driven by the potential integration of its chips into future AI-agentic smartphone platforms and broader AI infrastructure. While the community is actively debating the stock's valuation and the company's long-term competitive positioning, investors are closely watching upcoming earnings as a potential catalyst to clear current overhead supply.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant retail attention driven by high volatility and heavy short interest, leading traders to discuss the potential for a short squeeze despite skepticism surrounding the company's fundamentals and recent price action. The community remains divided, with some actively trading the sharp price swings while others warn of the risks associated with the stock's unpredictable performance.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing high volatility as investors weigh the potential for government contract awards against frustration with management's communication regarding timelines and guidance. The community is focused on the company's drone integration with U.S. military platforms and remains split between optimism for future revenue growth and skepticism over the timing of major defense milestones.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened selling pressure and negative sentiment due to concerns over regulatory uncertainty, particularly regarding the impact of proposed legislation and the competitive landscape of prediction markets. Community discourse remains deeply divided, with bearish investors citing management's consistent share selling and weak stock performance, while long-term bulls point to potential expansion opportunities and the belief that the stock is currently undervalued.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors following the release of positive Phase 3 clinical trial results, though the stock's price action has been marked by high volatility and intense debate among traders. While the community is actively discussing the company's long-term potential in gene-editing, significant disagreement persists over the efficacy of the data, the impact of potential dilution from an at-the-market offering, and the heavy influence of short sellers on the stock's movement.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention following positive Phase 3 clinical trial results for its acne treatment and ongoing developments in its MASH pipeline, including combination therapy efforts. The community is actively debating the stock's potential for acquisition, with discussions highlighting its discounted valuation relative to other MASH-focused biotech buyouts and its recent analyst upgrades.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is experiencing significant community momentum as investors anticipate the official U.S. launch of its predictive betting platform, a move bolstered by recent strategic marketing partnerships. Market participants are actively discussing a potential squeeze driven by a tight float, high short interest, and the stock's positioning as a pure-play opportunity in the rapidly expanding predictive betting sector.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the company accelerates its New York flight campaign and secures key regulatory approvals for operations, fueling optimism among investors tracking its progress toward commercial launch. While community sentiment is heavily polarized between long-term supporters focused on these engineering milestones and skeptics pointing to high cash burn and technical volatility, traders are actively monitoring the stock's significant options activity and price action around key resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Breakthroughs and Energy Deals Send These Stocks Soaring

A powerful wave of dealmaking, clinical breakthroughs, and infrastructure buildouts is driving renewed momentum with companies spanning energy, biotech, semiconductors, and AI ecosystems delivering headline-making developments. $USEG, $QUIK, $KBLB, $YAAS, $SGMT, $DKI, $GLND

<ul class="summary-bullets"><li>Sagimet plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026 following positive late-stage results in China, which showed a favorable safety profile.</li><li>The biotech firm priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, a 2.4% premium over its closing price on Friday.</li><li>Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028.</li></ul>Shares of Sagimet Biosciences (SGMT) jumped more than 40% on Monday, breaking the 200-day moving average for the first time since early February, after the company priced its latest share offering at a premium and reported positive progress on its acne drug.<a href="https://stocktwits.com/symbol/SGMT">SGMT shares</a> recorded their biggest intraday gains in more than 27 months, rising to their highest levels in over 5 months.<img src="https://news.stocktwits-cdn.com/SGMT_jpg_9df53f672c.webp" alt="SGMT.jpg">Source: TradingView<h2 class="st-heading-2">$175M Offering To Boost Acne Treatment Pipeline</h2>Sagimet priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, aiming to raise roughly $175 million in gross proceeds. This represented a 2.4% premium to the stock’s closing price on Friday. The offering is expected to close around April 28, 2026.The clinical-stage biotech firm plans to use the funds to advance its pipeline, including a Phase 3 trial of its lead drug candidate Denifanstat for acne. Proceeds will also support the development of TVB-3567, a small-molecule inhibitor of fatty acid synthase (FASN) for acne treatment.Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028, including key trial readouts. The remaining funds will be used for general corporate purposes, including clinical development, working capital, and operating expenses.<h2 class="st-heading-2">Denisfanstat Acne Treatment In Focus</h2>Sagimet is advancing its acne treatment pipeline, with plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026. The move follows positive late-stage results in China, where the once-daily oral therapy showed good safety and sustained improvement in patients with moderate to severe acne.The company is also progressing its broader pipeline. Sagiment announced plans to move its TVB-3567, currently in a Phase 1 trial, into Phase 2 studies later this year. Meanwhile, development in metabolic dysfunction-associated steatohepatitis (MASH) is expected to be paused until the company secures non-dilutive funding.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform remained ‘extremely high.’One user said the company’s acne treatment “has blockbuster potential.”<stembedurl>https://stocktwits.com/Expharmaguy/message/651485936</stembedurl>Another user said SGMT is “now a $50-100 value stock” given the “resoundingly positive phase 3” trial.<stembedurl>https://stocktwits.com/Market_Max/message/651490482</stembedurl>The stock has gained around 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-elon-musk-pay-package-share-registration-what-it-means/cZBNYDmReP3">TSLA Stock In Spotlight As EV Maker Registers Shares Tied To Elon Musk’s 2018 Pay Package – Retail Sees Imminent Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

The firm announced positive late-stage results in China for its lead drug candidate to treat acne, and priced its $175M offering at a premium. 

Equity

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a...

Sagimet Names Andreas Grauer CMO

(RTTNews) - Sagimet Biosciences Inc. (SGMT), on Monday announced the appointment of Andreas Grauer as Chief Medical Officer, effective April 20...

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Down 15.2% in March

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) saw a significant decrease in short interest in March. As of March 31st, there was short interest totaling 3,225,311 shares, a decrease of...

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven brokerages that are currently covering the firm...

Sagimet Biosciences (NASDAQ:SGMT) Now Covered by Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Sagimet Biosciences in a research report on Thursday. They set a "buy" rating and a $28.00 price objective for the company...

Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday

Sagimet Biosciences (NASDAQ:SGMT) will be releasing its Q4 2025 earnings on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-sagimet-biosciences-inc-series-a-stock...

HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Analysts at HC Wainwright dropped their FY2027 earnings per share (EPS) estimates for Sagimet Biosciences in a report issued on Wednesday, March...

Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Sagimet Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

Earnings

Fed / Macro data

Headlines / Geopolitics

Other (drop a comment)

What will be the main driver of the market this week?

Stocktwits

Stocktwits Polls

The stock surged following a $175 million equity offering, with investors interpreting the capital raise as a validation of the company's acne drug trial progress.

Strategic updates regarding the initiation of Phase 3 clinical trials for denifanstat have generated significant enthusiasm regarding the drug's blockbuster potential.

Some market participants remain skeptical of the rally, labeling the price movement a 'pump and dump' and citing the $6.00 offering price as a ceiling for current momentum.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.37	--	--	N/A
Q4 '25	-$0.43	-$0.29	32.90%	BEAT
Q3 '25	-$0.39	-$0.40	-3.63%	MISSED
Q2 '25	-$0.51	-$0.32	37.05%	BEAT
Q1 '25	-$0.67	-$0.56	15.91%	BEAT

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SGMT News

SGMTSagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Historical Earnings

Latest SGMT News

SGMT
Sagimet Biosciences Inc